Glaukos Corporation
Founded in 1998, Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.
See below for the Latest Glaukos Corporation News, Analysis, Profit Results, Share Price Information, and Commentary.
Micro stents, macro efficiency: How a tiny device helps preserve vision
Micro stents, macro efficiency: How a tiny device helps preserve vision
Glaukos Corporation’s iStent inject W helps preserve vision by addressing high eye pressure.
Join the community
Most Read
1. Asian medical device markets face cost shocks amidst Iran conflict 2. Gene and cell therapy boom drives DNA manufacturing market toward $21.82B by 2034 3. HSA to expand role in accelerating biomedical sector growth: Ong Ye Kung 4. Global dental articulators market to reach $227.8m by 2030 5. AJJ Medtech hits $8m order book with $3m green supply dealResource Center
Events
Event News
Co-Written / Partner
Pureland Venture’s Chris Hardesty: Governments must sustain long-term focus on healthcare innovation, technology
He discusses how healthcare systems in Asia Pacific need to evolve beyond simply expanding coverage and towards delivering equitable, sustainable, and high-impact care.
Commentary
Beyond ChatGPT: The rise of multimodal AI assistants in clinical settings
2026 biotech playbook: Hong Kong at the centre of China’s globalisation